Definium TherapeuticsDFTX
Recorded

Definium Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Andrew TsaiAnalyst

Okay, we're going to get started. Welcome to day two of our London Healthcare Conference. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have Rob Barrow, CEO of Definium.

Rob BarrowCEO

Welcome, Rob. Thanks so much, Andrew.

Andrew TsaiAnalyst

I think a lot of us are familiar with the Definium story, but there might be a few people who are unfamiliar. Would you mind talking about what you're working on, how you are differentiated out there, what catalysts we can expect over the next 6-12 months? That'd be very helpful. Yeah, absolutely.

Rob BarrowCEO

Definium is developing our lead program. We have a few programs in the clinic. Our lead program is a proprietary form, an ODT of LSD. Obviously, the drug has been around for about 80 years, but we've brought back into the clinic. Over the summer, we had three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. We also just released some preliminary data from our second program, R-MDMA and autism spectrum disorder. Five patients where we saw a really clear signal and are now advancing that further into the clinic. Part of a broader, really exciting phase of psychiatry where this is a reinvigoration of a field that hasn't had anything new in a very long time. In GAD especially, there hasn't been a new approval in 20 years almost.

Rob BarrowCEO

To bring a drug that we've now seen over those studies, the largest effect in both indications ever in a pivotal study with a single dose of drug. Patients are in the clinic for, on average, about six hours and then go about their lives, and a big portion of those patients are meaningfully better for a very long time with just one or a few doses. This entirely new paradigm is obviously moving into a world of interventional psychiatry that has really come into its own in the last several years and had extraordinary excitement for the field. Now with this kind of evidence, we're taking the next step. We're progressing over the next 6-12 months. We'll have, in 2027, a readout from our fourth pivotal study, our second study in major depressive disorder.

Rob BarrowCEO

We expect to be filing our NDA in the first half of next year, and we're getting ready to, assuming we get the drug approved, be ready to go launch this in a really meaningful way.

Andrew TsaiAnalyst

Okay, thanks. Like you said, two successful GAD datasets, phase III, and then one phase III major depression dataset right now. As we think about the market opportunity, can you just remind us in your internal models how many patients you would need to get to a billion in peak sales? What's that pricing bookend look like?

Rob BarrowCEO

Yeah, obviously, we haven't announced a price of the drug, given where we are. But when we look at analogs out in the world, I mean, intranasal esketamine is one that, for a lot of reasons, has its limitations as an analog, but in many cases, it's a reasonable thing to look to. This is J&J's SPRAVATO. Now doing about $2 billion in annual revenues with that product. Pricing range tends to be in the $30,000-$70,000 range. So midpoint around $50,000 a year. Obviously, some different dynamics, up to 56 doses a year for that drug versus just a few for ours. When we talk about pricing and think about annual pricing, it's just an analog that is easier to point to that's out in the world for a new branded and interventional psychiatry drug.

Rob BarrowCEO

Obviously, if you use that number, you don't need many patients to get to some really meaningful revenue numbers. Given the market opportunity, there are 50 million patients in the U.S. alone with these two disorders. About half of them are diagnosed, about half of those are treated, about a third of those have not responded to two or more drugs and would easily make it through to a step three therapy. It's about 4 million patients, obviously, to get to again, some really eye-watering numbers of patients that we can hopefully help translates into meaningful revenue.

Andrew TsaiAnalyst

Great. As we look ahead, I notice you mentioned you're filing an NDA in first half 2027, but you didn't necessarily specify whether it's for GAD or MDD or GAD plus MDD. I think at one point very recently, you've entertained the notion that maybe you could file jointly for both MDD and GAD together based on the three datasets you have. Is that still a possibility in your view?

Rob BarrowCEO

Yeah, we got a number of options available to us. I mean, our focus, we really think about the end goal here, which is the opportunity to launch a drug really for the first time that we're aware of with both generalized anxiety disorder and major depressive disorder on the label. Most of the times, they're staggered by several years. Typically, for the last class of drugs for SSRIs, it started with depression, moved into anxiety over time. If successful, we could end up in a place where we're launching DT120 for both indications, two of the biggest markets in all of psychiatry, and maybe all of medicine, given the scope of how many people this affects. Filing strategy is something we have, as we said, we have a pre-NDA meeting in the fourth quarter.

Rob BarrowCEO

Once we have minutes in hand, we'll be able to provide more granular clarity on that. A few different possibilities there, and we obviously have the second MDD study in depression that we'll be reading out in 2027. A few different paths. One would be to file concurrently. The original plan, as we conceived of the program, we had started our GAD program so far in advance of MDD, we were planning initially to file GAD first and file an sNDA with MDD, assuming we get the GAD indication approved. The third possibility is that we stagger the filing. With a controlled substance, after approval, there's a 90-day window where DEA has to take action, issue a schedule for the drug before it can actually go and be marketed.

Rob BarrowCEO

There's another path where we could actually stagger the submissions, not submit them together, but also end up in the same situation where we're launching them together. Any number of those could remain on the table and will provide some additional clarity, and also intersects with the timing of the second MDD data, because we want to have that upside opportunity to get those on the label, but also want to present the most compelling data package to FDA and to clinicians, to everyone, so that if we're successful in that, we have the strongest body of evidence to stand behind.

Andrew TsaiAnalyst

Okay. The plan is you're talking to the FDA in Q4. We're in the middle of November. Have you spoken to the FDA?

Rob BarrowCEO

We have been talking about it, I think, as we come out with minutes. One of the things, we have such a great dialogue and such a great relationship with the review division, with psychiatry at FDA. They've been incredibly thoughtful leaders and partners, I think, for the entire field, and certainly for us. I didn't mention, we have Breakthrough Therapy designation for both of these programs. That gives us an opportunity to engage with FDA on a really nearly ongoing basis, I mean, really frequently. We've taken that opportunity, and they've, again, shown up and been great partners and provided that ongoing feedback. While we haven't said exactly which meetings we've had when, we have a frequent and ongoing dialogue that constructively moves us in the direction of having a clear path.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day